China Health Group Inc. is a leading provider of new drug technology products and sales market services in China. The company is dedicated to global raw material medicine and formulation technology development services, clinical research services, and drug registration services. China Health Group is also one of the few internationally listed pharmaceutical companies in Hong Kong driven by research and development (stock code: 8225). Since its establishment in 1998, the company has developed seven VSmart® drug delivery system technology platforms. It has completed over 300 national-level preclinical studies for new drugs in China, applied for over 100 domestic and international invention patents, and conducted preclinical research for six innovative drugs. The company has obtained nearly 100 national-level new drug certificates and production licenses, including first-class new drugs, and has been recognized as a leader in new drug development by the industry's official media, "China Pharmaceutical News." China Health Group is gradually establishing a global and comprehensive pharmaceutical enterprise and was selected as one of the five companies with amazing potential in China by the Chinese version of the authoritative magazine "Fortune" and the famous financial magazine "Digital Fortune" in 2002. It is also considered one of the companies with the potential to become one of the top 10 large companies in China in the future.
Headquarters
No.3 Jinzhuang, Si Ji Qing, Haidian District
Beijing; Beijing;
Postal Code: 100089
Contact Details: Purchase the China Health Group Inc. report to view the information.
Website: http://www.chgi.net
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service